Current Context : Australia has approved the use of Lecanemab, a new drug for treating early-stage Alzheimer’s disease, aimed at slowing its progression.

ABOUT LECANEMAB DRUG

• Nature
  • A monoclonal antibody drug.
  • Administered intravenously (IV) through a drip bag.
• Working
  • Targets amyloid proteins in the brain.
  • Works with brain immune cells to clear amyloid build-up.
  • Shown to reduce disease progression by 27% in clinical trials.
• Issues
  • High cost and limited accessibility.
  • Potential side effects like brain swelling.

ABOUT ALZHEIMER’S DISEASE

• A progressive brain disorder that destroys memory and thinking skills.
• Most common cause of dementia (60–80% of cases).
• Usually affects people 65+ years; 10% of cases occur below this age.
• Symptoms caused by toxic amyloid protein build-up damaging brain cells.